

# Rheumatoid Arthritis and Related Testing

Test Name	Test No.
14-3-3 eta, Rheumatoid Arthritis	504550
Anti-Carbamylated Protein (CarP) Antibody	520311
Anti-CCP (Cyclic Citrullinated Peptide) Antibodies	164914
Anti-CEP-1 Ab, IgG (RDL)	520133
Anti-Sa Ab, IgG (RDL)	520081
Hydroxychloroquine, Whole Blood	504814
Methotrexate polyglutamates	504104
QuantiFERON®-TB Gold Plus	182879
RA Profile with reflex to SeroNeg RAdx4 Profile	520298
RAdx6 Profile	520304
RheumAssure®	504509
Rheumatoid Factor (RF)	006502
SeroNeg RAdx4 Profile	520305
Thiopurine Metabolites	503800
Thiopurine Methyltransferase (TPMT), Enzyme Activity, Erythrocytes	510750
Thiopurine Methyltransferase (TPMT) Genotyping	508080
Vectra®	504965
Vectra® with CV Risk	504980
<b>DoseASSURE™</b>	
Adalimumab and Anti-Adalimumab Antibody (Serial Monitor), DoseASSURE™ ADL	503890
Certolizumab and Anti-Certolizumab Antibody, DoseASSURE™ CTZ	504627
Etanercept and Anti-Etanercept Antibody (Serial Monitor), DoseASSURE™ ETN	504245
Golimumab and Anti-Golimumab Antibody, DoseASSURE™ GOL	504563
Infliximab and Anti-Infliximab Antibody (Serial Monitor), DoseASSURE™ IFX	503870
Rituximab and Anti-Rituximab Antibody, DoseASSURE™ RTX	504355
Ustekinumab and Anti-Ustekinumab Antibody, DoseASSURE™ UST	504594
Pre-Biologic Screening Profile	144441

## References

- Handout on Health: Rheumatoid Arthritis. National Institute of Arthritis and Musculoskeletal and Skin Diseases Website [http://www.niams.nih.gov/health\\_info/Rheumatic\\_Disease/default.asp#ra\\_2](http://www.niams.nih.gov/health_info/Rheumatic_Disease/default.asp#ra_2). Accessed February 25, 2014.
- Aletha D, Neogi T, Silman AJ. 2010 rheumatoid arthritis classification criteria. *Arthritis Rheum*. 2010;62(9):2569-2581.
- Maksymowych WP, Naides SJ, Bykerk V, Siminovich KA, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. *J Rheumatol*. 2014 Nov;41(11):2104-13. doi: 10.3899/jrheum.131446. Epub 2014 Aug 15. PMID: 25128504.
- Carrier N, Marotta A, de Brum-Fernandes AJ, Liang P, Masetto A, Ménard HA, Maksymowych WP, Boire G. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. *Arthritis Res Ther*. 2016 Feb 1;18:37. doi: 10.1186/s13075-016-0935-z. PMID: 26832367; PMCID: PMC4736641.
- Curtis JR, Weinblatt ME, Shadick NA, et al. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. *Arthritis Res Ther* 23, 1 (2021). <https://doi.org/10.1186/s13075-020-02389-4>.
- Curtis JR, Xie F, Crowson CS, et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. *Arthritis Res Ther* 22, 282 (2020). <https://doi.org/10.1186/s13075-020-02355-0>.

- Goodman S. Measuring methotrexate polyglutamates. *Clin Exp Rheumatol*. 2010 Sep-Oct; 28 (5 Suppl 61): S24-S26.
- De Rotte MCFJ, den Boer E, de Jong PHP, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2013;0:1-7.
- Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. *Inflamm Bowel Dis*. 2011 Jun; 17(6): 1428-1435.
- Vincent FB, et al. Antidrug antibodies to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. *Ann Rheum Dis* 2013;72:165-178.
- Mulleman D, et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. *Arthritis Res Therapy* 2009;11(6):R178.
- Chen DY, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. *Ann Rheum Dis* 2015;74:e16.
- Mulleman D, et al. Should anti-TNF-a drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? *Joint Bone Spine* 2012;79:109-112.
- Krieckaert CLM, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. *Ann Rheum Dis* 2015;74:361-368.
- Kneepkens EL, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. *Ann Rheum Dis* 2015;74:1825-1829.

For more information, contact your Labcorp sales representative or visit **Labcorp.com**.

